AVI-4658 is to skip for exon 51 of the dystrophin gene http://nolvadex.eu/nolvadex-dans-la-musculation.html.

AVI-4658 is to skip for exon 51 of the dystrophin gene, so that the restoration of the reading frame of the mRNA sequence http://nolvadex.eu/nolvadex-dans-la-musculation.html . By skipping this exon a truncated but potentially functional form of the dystrophin protein is produced to improve what the disease process and possibly prolong and improve the quality of life of these patients. Results from a Phase 1 proof-of-concept study showed that the injection of the drug into the muscles of a successfully series of DMD boys induced dystrophin production in a dose-responsive manner. Further, the drug was well tolerated, with no significant recorded drug-related adverse events. The clinical in collaboration with the in collaboration with the MDEX Consortium in London, UK. AVI is also developing AVI-5038, a new drug candidate for the second generation PPMO chemistry based and designed to exon skipping 50th The preclinical work for AVI-5038 is Charlie Charlie. The company is currently working on this new in clinical in clinical trials to advance under an Investigational New Drug Application in the United States and an Investigational Medicinal Product Dossier in Europe.

‘AVI and Action Duchenne share a common goal new therapeutics new therapeutics we find treatment options for DMD patients, we believe that such cooperation has great potential, ‘said Leslie Hudson, President and Chief Executive Officer of AVI BioPharma. ‘and we are also very pleased with the financial support of action Duchenne, the receive to accelerate our research and development efforts for new exon skipping therapeutics. ‘.


M. Comments for Boehringer Ingelheim Clinical Test Results in the treatment of Female Sexual Dysfunction.